anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Autism is a complex neuro-developmental disorder of early childhood onset characterized by impairments in the core triad of social interaction, repetitive-stereotypes behaviors, and verbal/nonverbal communication. This major public health concern exerts an enormous toll on the quality of life of affected individuals, families, and society. Though there are medications available for use in managing autism associated behaviors, including aggression, self-injury and hyperactivity, there are no medical treatments of proven benefit in treating core autistic features such as social and communication deficits. Complementary and alternative medical treatments(CAM) are commonly used by individuals with a wide variety of medical diseases including autism despite little evidence-based support for their efficacy. Recent surveys reveal the prevalence of CAM use in children with autism to be between 30% and 95%. Osteopathic Manual Medicine (OMM) is one of the most well studied CAM treatments, achieving widening acceptance with increasing evidence of safety and efficacy, as an adjunct in the treatment of a number of conditions. OMM appears to be a safe treatment modality in the pediatric population when administered by physicians with expertise in OMM. At a physiologic level, OMM has been proposed to elicit some of its therapeutic and biomechanical effects through an ability to mobilize body fluids, increase removal of metabolic waste, and boost immune function. OMM has been shown to have favorable effects on neuro-endocrine and immunologic function. As theories of autism pathogenesis often revolve around immune dysregulation including lowered IgA levels, and accumulation of metabolic and xenobiotic agents, there are theoretical mechanisms through which OMM can exert therapeutic effects. In practice, OMM has been shown to improve sensory and motor performance with neurological problems, including autism. Additionally, studies of manual medicine techniques similar in principle to OMM, including Qigong massage and Tuina, have yielded favorable outcomes on a number of core autistic features including social, language, sensory, cognition and self-care domains as measured by the Autism Behavior Checklist (ABC) and Functional Independence Measures for Children(WeeFIM). 30 subjects will be randomized to receive OMM or sham treatments. Standardized assessment tools for autism symptom severity (ABC and WeeFIM) will be administered pre- and post-study to compare treatment efficacy between arm. Saliva samples will be collected pre- and post-treatment sessions to evaluate biochemical response and to catalog genetic markers that could provide insight into subsets exhibiting differential response.
FIELD: medicine. ^ SUBSTANCE: invention refers to medicine, namely to oncology, and can be used in treating the patients with Non Hodgkin Lymphoma. That is ensured by administration of a combination containing an effective amount of CCI-779 and rituximab in the form of a dosage form with one or more neutral components added. The combination is introduced simultaneously, separately or consistently with the other agents. ^ EFFECT: method allows improving clinical effectiveness for the given pathology, including in the patients resistant to rituximab due to synergetic interactions of these preparations. ^ 5 cl
Patients undergo hypofractionated stereotactic body radiation therapy in 5 fractions on days 1-5. Patients receive fluorouracil IV over 24 hours on day 1 weekly for 4 weeks or capecitabine PO every 12 hours starting the evening before day 1 of radiation therapy for 4 weeks as per standard of care. Patients then undergo surgery 6-8 weeks after completion of radiation therapy.
FIELD: medicine.SUBSTANCE: invention refers to medicine, namely to sports medicine, and can be used for weight reduction in obesity patients. Dynamic load is a complex of physical exercises, which makes 40 hours of training, each training including 20–30 minutes of cardioplasty and 30–40 minutes of power load. Training sessions are three times a week. Each feeding stage makes one month. In the first month, daily food intake makes 100 g of complex carbohydrates, 100 g of proteins, and 30 g of fats for one meal, and the drinking regime makes at least 2 litres of water a day. During the second month, carbohydrate content is reduced weekly. During the third month, protein-carbohydrate alternation of food is performed during the first week, not exceeding 1100 kcal a day, and during the second and third weeks of the third month, the menu, multiplicity and weight of the first month's food intake are stored. During the second and third weeks of the month, calculating the number of kilocalories in relation to human growth, and in the fourth week of the third month, consumption of carbohydrates is excluded and additionally water consumption is reduced to 2 litres a day. On the last day of the week one consumes not more than 1 litre of water a day. First week of the second month consumes 100 g of carbohydrates in the permitted products during the day, the second week - 90 g of carbohydrates during the day, third - 80 g of carbohydrates during the day and fourth - 70 g of carbohydrates during the day. Ratio of the consumption of kilocalories to the human growth is 1000 kcal to 160 cm; with growth of 160 cm to 170 cm - 1200 kcal; with growth from 170 to 180 cm - 1400 kcal and with growth above 180 cm - 1600 kcal.EFFECT: method provides higher availability and convenience of method implementation for program participants due to alternation and balance of power supply stages.3 cl, 3 ex, 3 dwg
The invention relates to a cyclic color-threo-valyl-Leu peptide (Trp-Thr-Val-Leu-Leu cyclic peptide) with hepatoma cytotoxicity and alpha-glucosidase inhibition activity and a preparation method thereof, belonging to the technical field of extraction and preparation of biological products. The cyclic-threo-valyl-leu peptide is fifteen-membered cyclic pentapeptide formed by connecting tryptophan, threonine, valine, leucine and leucine through an amide bond. This is a novel compound and has not been reported in the literature. The compound can be obtained by culturing frog-feces mould, and then extracting and separating. The pure product of the cyclophilin-threo-valyl-leucinyl peptide is white powder, and the half inhibition concentration (IC  50 ) of the cyclophilin-threo-valyl-leucinyl peptide on liver cancer cells HepG2 is as follows: 51.50 μg/mL, half inhibitory concentration of α -glucosidase (IC  50 ) was: 140.81 μg/mL. The compound can be used as potential medicine for treating liver cancer and slimming medicine.
Familial hypercholesterolemia (FH) is a common inherited disorder with a frequency of 1 in 500 in the UK. Previous Studies showed that risk of heart attack in these patients is at least 50% higher in men and 30% higher in women compared to the general population as they have high blood cholesterol since birth. We propose to develop a screening model based on non-invasive visualisation of the heart blood vessels (coronary arteries) by CT scan, ultrasound of the neck vessels (carotid arteries) and blood tests to access the extend of cholesterol deposit in the blood vessels in these patients. Participants with confirmed diagnosis of FH would be recruited from FH database registry at Royal Free Hospital. They would have a CT coronary angiogram, an ultrasound of carotid arteries and a blood test. The study is divided into overlapping stages of recruitment and data collection and data analysis. If CT scan shows more than 70% obstruction in their coronary arteries, they would be offered a coronary angiogram and an intracoronary Optical Coherence Tomography for assessment of their blood vessel blockage.
Preparation of N-dialkylamino- or N-heterocyclic-substituted maleic or isomaleic imides by reacting a maleic acid monohydrazide of the formula <FORM:1116173/C2/1> where R1 and R2 each represents an alkyl group or together with the nitrogen atom to which they are attached form a heterocyclic ring optionally containing a further hetero atom, in a solvent at a temperature from - 10 DEG  to + 50 DEG  C., with an amido-chloride derived from a carboxylic acid.  The amido-chloride is preferably prepared from an N,N-disubstituted carboxylic acid amide particularly a N,N-dialkyl-substituted formamide, e.g. dimethylformamide, by the action of an inorganic acid chloride such as thionyl chloride, phosgene, phosphorous oxychloride or phosphorus pentachloride and is not purified prior to use.  The reaction may be carried out in an N,N-disubstituted carboxylic acid amide solvent preferably the amide from which the amido-chloride is derived.  The preparation of N-dimethylamino-and N-morpholyl-maleic imide and N-tetrahydrothiazinylisomaleic imide dioxide is described.ALSO:Anti - microbial N - (di - substituted - amino) - maleic imides are obtained by reacting a compound of the formula:  <FORM:1116173/A5-A6/1> wherein R1 and R2 each represent an alkyl group with an amido chloride derived from a carboxylic acid.  In particular, N - dimethylamino - maleic imide is totally germicidal when added 1:4000 to innoculated optimum nutrient solutions of Bacterium coli, Pseudomonas pyocyanea, Bacillus subtilis, Trichophyton mentagrophytes and Saccaromyces.
The invention relates to a slow release preparation which uses pseudoephedrine or physiologically acceptable salts and chlorpheniramine or physiologically acceptable salts as active ingredients. The preparation is characterized in that the slow release system comprises a pill core and/or a coating which enable drugs to slowly release; and all active ingredients are stored in the pill core. The slow release preparation can not only fully overcome the symptoms related to colds and play the synergic effect of the compound drugs, but also realize synchronization of release and absorption of three active ingredients and achieve the expected drug releasing activity inside or outside the body. The administration times can be reduced by the drug releasing activity (from four times one day to twice one day, i.e. taking once respectively on morning and at night). The invention has the advantages of few drug taking times, slow release of the drugs in the body, stable blood and drug concentration, small fluctuation, high biological utilization degree and high safety.
Patients will undergo the standard CTA protocol and invasive coronary angiography performed as part of the pre-operative assessment for TAVR. Patients in this study will also undergo DynaCT during coronary angiography, utilizing 1 acquisition sweep and 20 to 35cc more of contrast media. Measurements of the major aortic annulus diameter, orthogonal minor aortic annulus diameter, aortic annulus perimeter, maximum ascending aorta diameter at 40mm above the annulus, sinus of Valsalva diameters, sinus of Valsalva heights, and aortic root angulation will be made using both the CTA and DynaCT protocols by a radiologist blinded to patient identity. Based on these measurements, a trained interventional cardiologist will select the appropriate TAVR size for the patient.
A global rise in the prevalence of patients with chronic kidney disease (CKD) with end-stage kidney disease (ESKD) has led to a considerable and increasing burden to health systems, patients, and society. Sodium-glucose cotransporter 2 (SGLT2) inhibitors are proven to reduce incidence of cardio-renal outcomes, including onset of ESKD. Recent post hoc analyses of SGLT2 inhibitor trials extrapolate substantial delays in the average time to ESKD over a patient's lifetime. In this article, we explore the possible real-world effects of such a delay by considering the available evidence reporting outcomes following onset of ESKD. From the patient perspective, a delay in reaching ESKD could substantially improve health-related quality of life and result in additional life years without the need for kidney replacement therapies, a target relevant to all CKD subpopulations. Furthermore, should a patient initiate dialysis at an older age as a result of CKD progression, the time spent in receipt of dialysis, and therefore associated healthcare costs, may also be reduced. A delay in progression may also lead to changes in the management of ESKD, such as increased election of conservative care in preference to dialysis, particularly in elderly populations. For younger patients with CKD, those who reach ESKD while employed face considerable work impairment and productivity loss, as may families and care partners of working age. Therefore, a delay to the onset of ESKD will reduce the proportion of their working lives affected by productivity losses or unemployment due to medical reasons. In conclusion, optimised treatment of CKD may lead to a shift in treatment options, but proper and timely implementation is essential for the realisation of improved outcomes.
MicroRNAs (miRNAs) are 18-25 nucleotides long, single-stranded, non-coding RNA molecules that regulate gene expression. They play a crucial role in maintaining normal cellular functions and homeostasis in organisms. Studies have shown that miR-124-3p is highly expressed in brain tissue and plays a significant role in nervous system development. It is also described as a tumor suppressor, regulating biological processes like cancer cell proliferation, apoptosis, migration, and invasion by controlling multiple downstream target genes. miR-124-3p has been found to be involved in the progression of various kidney diseases, including diabetic kidney disease, calcium oxalate kidney stones, acute kidney injury, lupus nephritis, and renal interstitial fibrosis. It mediates these processes through mechanisms like oxidative stress, inflammation, autophagy, and ferroptosis. To lay the foundation for future therapeutic strategies, this research group reviewed recent studies on the functional roles of miR-124-3p in renal diseases and the regulation of its downstream target genes. Additionally, the feasibility, limitations, and potential application of miR-124-3p as a diagnostic biomarker and therapeutic target were thoroughly investigated.
General: Celecoxib metabolism is predominantly mediated via cytochrome P450 (CYP) 2C9 in the liver. Co-administration of celecoxib with drugs that are known to inhibit CYP2C9 should be done with caution. Significant interactions may occur when celecoxib is administered together with drugs that inhibit CYP2C9. In vitro studies indicate that celecoxib, although not a substrate, is an inhibitor of CYP2D6. Therefore, there is a potential for an in vivo drug interaction with drugs that are metabolized by CYP2D6.

In vitro studies indicate that celecoxib, although not a substrate, is an inhibitor of CYP2D6. Therefore, there is a potential for an in vivo drug interaction with drugs that are metabolized by CYP2D6.
Measurement of myocardial levels of enzyme nitric oxide synthase(iNOS) using PET and 18F-NOS in post heart transplant patients (5 women and 5 men) undergoing endomyocardial biopsy as part of their normal post-transplant evaluation. Kinetic data of the tracer will be compared with the heart tissue measurements of iNOS measured by immunohistochemistry.
Current methods for combatting infectious diseases are largely limited to the prevention of infection, enhancing host immunity (via vaccination), and administration of small molecules to slow the growth of or kill pathogens (e.g. antimicrobials). Beyond efforts to deter the rise of antimicrobial resistance, little consideration is given to pathogen evolution. Natural selection will favor different levels of virulence under different circumstances. Experimental studies and a wealth of theoretical work have identified many likely evolutionary determinants of virulence. Some of these, such as transmission dynamics, are amenable to modification by clinicians and public health practitioners. In this article, we provide a conceptual overview of virulence, followed by an analysis of modifiable evolutionary determinants of virulence including vaccinations, antibiotics, and transmission dynamics. Finally, we discuss both the importance and limitations of taking an evolutionary approach to reducing pathogen virulence.
Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) is a common pelvic pain syndrome in males, seriously affecting patients' quality of life. For a long time, CP/CPPS has been considered a complex and variable disease, and its pathogenesis remains incompletely understood. Currently, CP/CPPS is believed to be a group of diseases characterized by pelvic pain or discomfort, urinary abnormalities, and other symptoms, each with its unique etiology, clinical characteristics, and outcomes, likely resulting from the action of pathogens or (and) certain non-infectious factors. Traditionally, CP/CPPS was thought to be unrelated to bacterial infections. However, in recent years, with the development of microbiology and the advancement of high-throughput sequencing technology, an increasing number of studies have suggested that microorganisms in the reproductive system may play an important role in the pathogenesis of CP/CPPS. The unique characteristics of CP/CPPS, such as its refractory nature and tendency to recur, may be closely related to the microbiota and their biological functions in the reproductive system. The relationship between CP/CPPS and reproductive system microorganisms is one of the current hot topics in microbiology and urology, receiving considerable attention from scholars in recent years and making a series of new advances. Through this review, we will comprehensively explore the relationship between CP/CPPS and reproductive system microorganisms, and look forward to future research directions, aiming to provide new ideas and methods for clinical diagnosis and treatment, thereby improving the treatment outcomes and quality of life of CP/CPPS patients.
In participants with solid non-melanoma, non- hematologic tumors who previously developed primary or secondary resistance to an anti-PD-1 or anti-PD-L1 agent, cobimetinib will be administered at the approved dose and schedule of 60 mg QD for 21 days and 7 days off of each 28-day cycle. The first dose of atezolizumab of 840 mg by IV infusions on Day 15 of Cycle 1. Thereafter, they will receive atezolizumab 840 mg IV infusion Q2W on Days 1 and 15 of Cycle 2 and all subsequent cycles.
The training module will consist of 3 sessions. The first session will last 1 hour, with 45 minutes of interactive lecture and 15 minutes of question and answer. The second and third sessions will last 1 hour, with 45 minutes of interactive narration and 15 minutes of qualitative interviews. Module sessions will have a dynamic structure that takes into account the needs of the pregnant woman in her trimester. The content of the training sessions will be structured on the following topics.
Deep brain stimulation (DBS) is an increasingly common surgical technique for the treatment of Parkinson's disease and dystonia. The current technical approach to DBS implantation involves frame-based stereotaxy. In this method, a stereotactic frame is rigidly fixed to the patient's skull, an MRI is obtained, an anatomic target is identified, and the coordinates of the target in stereotactic space are calculated. Instruments are mounted on the stereotactic frame that point to the calculated coordinate. However, due to the inherent inaccuracies in standard frame-based stereotaxy, a complex 6-hour procedure then ensues to "map" the brain target with microelectrodes, place the lead, and return to the MR unit to confirm proper placement.

The goal of this project is to gather observational data on the iMRI DBS implantation technique and clinical outcomes. This already FDA-approved implantation technique for DBS will take place entirely within the Phillips 1.5T and a Siemens 3T open magnet MRI machine. Prior to study initiation, instrumentation and MR protocols were tested using a phantom head. In the proposed project, subthalamic nucleus or globus pallidus DBS implantations will be performed bilaterally in patients with Parkinson's disease or dystonia. Patients will be under general anesthesia. Targeting and lead verification are performed with imaging alone, without physiologic mapping. Data is to be gathered on the following: operative time, degree of benefit with bilateral implantation (changes in standard rating scales of motor disability), DBS voltage requirements, complications), and electrode location by MR. These measures will be compared with our historical controls, previously entered into our research database, in which electrodes were placed by the standard methods. We expect that the use of near real time MR will improve the speed and accuracy of DBS implantation, and eliminate the need for invasive physiological monitoring.

All of the study participants will be getting iMRI DBS implantation as a part of their standard of care and agree to have additional study data collected
Participants will be randomized on Day 1 of Treatment Period 1 to receive either a single 12 mg dose of perampanel IV infusion (60-minute duration) or a single 12 mg oral tablet after an overnight fast. Participants will then receive the alternative treatment on Day 43 of Treatment Period 2. Drug administration will be separated by a washout of at least 6 weeks between the 2 treatment periods.
The recommended dose is 8 mg/kg/day of the suspension. This may be administered as a single daily dose or may be given in two divided doses, as 4 mg/kg every 12 hours. 

Note: A suggested dose has been determined for each pediatric weight range. Refer to Table 1. Ensure all orders that specify a dose in milliliters include a concentration, because SUPRAX for oral suspension is available in three different concentrations (100 mg/5 mL, 200 mg/5 mL, and 500 mg/5 mL).

Children weighing more than 45 kg or older than 12 years should be treated with the recommended adult dose. SUPRAX (cefixime) chewable tablets must be chewed or crushed before swallowing.

Otitis media should be treated with the chewable tablets or suspension. Clinical trials of otitis media were conducted with the chewable tablets or suspension, and the chewable tablets or suspension results in higher peak blood levels than the tablet when administered at the same dose. 

Therefore, the tablet or capsule should not be substituted for the chewable tablets or suspension in the treatment of otitis media [see Clinical Pharmacology (12.3)].

In the treatment of infections due to Streptococcus pyogenes, a therapeutic dosage of cefixime should be administered for at least 10 days.